PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

BIOQUELL’S RAPID BIO-DECONTAMINATION SERVICE (RBDS) IS EFFECTIVE AGAINST CORONAVIRUS

Fully inclusive and managed RBDS uses Bioquell’s 35% hydrogen peroxide vapour solution to eliminate pathogens, providing a 6-log sporicidal kill

With the number of COVID-19 cases rising globally, Bioquell, an Ecolab solution (www.bioquell.com) – a leading manufacturer of high-performance bio-decontamination systems – is offering a proven solution to help eradicate coronavirus in a range of healthcare, life sciences and pharmaceutical environments, such as isolation rooms and public spaces.

Utilising the company’s scientifically proven 35% Hydrogen Peroxide Vapour technology, Bioquell’s Rapid Bio-decontamination Service (RBDS) is helping to provide microbiologically clean surfaces and spaces for patients and staff.

Surface contamination has been implicated in the transmission of certain viruses, including coronavirus, and surface de-contamination is an effective measure to interrupt the spread of these agents.

A study on the virucidal efficacy of Bioquell’s Hydrogen Peroxide Vapour was published in the April 2014 issue of The Journal of Hospital Infection. The study evaluated the in-vitro efficacy of Bioquell Hydrogen Peroxide Vapour for the in-activation of a number of structurally distinct viruses that could impact the healthcare, veterinary and public sectors, including feline calicivirus (FCV); human adenovirus type 1; transmissible gastroenteritis coronavirus of pigs (TGEV: a severe acute respiratory syndrome coronavirus (SARS-CoV surrogate); avian influenza virus (AIV); and swine influenza virus (SwIV).

The findings showed that after exposure to Bioquell’s Hydrogen Peroxide Vapour, no viable viruses were identified.

The technology also has been evaluated by the UK Government’s Biosafety Group at the Centre for Emergency Preparedness and Response, Porton Down, using the non-enveloped virus surrogate MS2 phage, with full inactivation achieved.

Respiratory viruses can contaminate and survive for long periods on environmental surfaces. Effective disinfection is essential for stopping transmission from the environment. However, this is not always achieved by conventional cleaning and disinfection techniques.

Bioquell’s Hydrogen Peroxide Vapour is a vapour-phase disinfection method that is virucidal on structurally distinct viruses dried on surfaces.

It achieves a level of efficacy unmatched by standard cleaning practices and other disinfection technologies. It is uniform across the entire target area and not limited to line-of-sight or easy-to-reach spaces.

Bioquell’s RBDS can be quickly called upon to eradicate coronavirus from a single area, several locations within a facility or an entire building. Using Bioquell’s 35% Hydrogen Peroxide Vapour solution (Bioquell HPV-AQ), it can eliminate pathogens, providing a 6-log sporicidal kill.

Through complete coverage of every exposed surface in an enclosed area, the process is residue-free, proven safe on sensitive electronics and shown to kill a wide range of microorganisms including bacteria, viruses, fungi, spores and more.

Bioquell’s RBDS offers the flexibility to retain or recover the microbial integrity of critical areas with every deployment including planning, co-ordination, setup, equipment, and cycle validation and verification. It provides a complete final report confirming a 6-log kill of the spaces and surfaces that have been treated with the use of biological and chemical indicators.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026